Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024

GAITHERSBURG, Md., Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, August 8, 2024. Details of the event and replay are as follows:

Conference call details:
Date:	August 8, 2024
Time:	8:30 a.m. U.S. ET
URL to register phone:	https://emportal.ink/3XTduSS
Dial-in number:	[phone] (Domestic) or
	(+1) [phone] (International)
Webcast:	ir.novavax.com/events

• Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
• Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
• To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.

Replay details:
Date:	Available starting at 11:30 a.m. ET, August 8, 2024, until 11:59 p.m. U.S. ET, August 15, 2024
Dial-in number:	[phone] (Domestic) or
	(+1) [phone] (International)
Passcode:	52500#
Webcast:	ir.novavax.com/events, until September 8, 2024

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors
Erika Schultz
240-268-2022
[e-mail]

Media
Giovanna Chandler
202-709-5563
[e-mail]

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-second-quarter-2024-financial-results-and-operational-highlights-on-august-8-2024-302212235.html

SOURCE Novavax, Inc.

Copyright 2024 PR Newswire